On February 11, 2021, Applied Therapeutics, Inc. (the "Company") reported that it entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Cowen and Company, LLC and UBS Securities LLC as representatives (the "Representatives") of the several underwriters named therein (the "Underwriters"), relating to the issuance and sale pursuant to an underwritten public offering (the "Offering") of an aggregate of 3,000,000 shares (the "Shares") of its common stock, par value $0.0001 per share (the "Common Stock"), and up to 450,000 additional shares of Common Stock at the Underwriters’ option (Filing, 8-K, Applied Therapeutics, FEB 11, 2021, View Source [SID1234575200]). The Shares were sold at a public offering price of $23.00 per share, less underwriting discounts and commissions, as described in the prospectus supplement, dated February 11, 2021, filed with the Securities and Exchange Commission (the "Commission") on February 12, 2021. The offering of Common Stock closed on February 17, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!